The first readout from Coegin Pharma's COAK phase I/II study in actinic keratosis has produced positive results. The top-line data indicates excellent safety and tolerance of AVX001 in 60 patients evaluated with two different doses. BioStock reached out to Coegin's CEO Tore Duvold to get his perspective on the data.

Read the interview with Coegin's CEO Tore Duvold at biostock.se:

https://www.biostock.se/en/2022/04/phase-i-ii-data-boosts-coegin-pharma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/coegin-pharma-ab/r/biostock--phase-i-ii-data-boosts-coegin-pharma,c3542973

(c) 2022 Cision. All rights reserved., source Press Releases - English